Study of AXT-1003 in Subjects With Advanced Malignant Tumors.
This is a Phase I study of AXT-1003 to assess the safety, tolerability, and pharmacokinetics in patients with advanced malignancies.
Trial Details
- NCT ID
- NCT06484985
- Phase
- PHASE1
- Sponsor
- Axter Therapeutics (Beijing) Co., Ltd
- Status
- RECRUITING
- Cancer Type
- Non-Hodgkin Lymphoma Lymphoma
- Interventions
- Locations (sample)
- Beijing, China|39.9075,116.39723
- Changsha, China|28.19874,112.97087
- Fuzhou, China|26.06139,119.30611
- Guangzhou, China|23.11667,113.25
- Shanghai, China|31.22222,121.45806
Key Eligibility Criteria
- For Ia dose escalation part only:
- R/R NHL: Locally histopathological diagnosis of relapsed/refractory non-Hodgkin lymphoma (R/R NHL), who have progressed or been intolerant after th…
- Advanced solid tumors: Locally histopathological diagnosis of locally advanced unresectable and metastatic solid tumors,The above subjects have pro…
- For Ib dose expansion part only: Subjects with relapsed/refractory peripheral T-cell lymphoma (R/R PTCL)
For full eligibility, visit ClinicalTrials.gov.